Antigenic modulation and receptor loss in experimental autoimmune myasthenia gravis
- PMID: 503104
- DOI: 10.1002/mus.880020304
Antigenic modulation and receptor loss in experimental autoimmune myasthenia gravis
Abstract
Immunization of groups of rats with 0.1- 100 microgram of acetylcholine receptor (AChR) purified from the electric organ of Torpedo californica resulted in dose-dependent (1) loss of acetylcholine receptor from the rats' muscles, (2) binding of antibodies to many of the receptors remaining in muscle and (3) production of antibodies in serum capable of cross-reacting with receptor solubilized from rat muscle. Addition of antibodies from rats immunized with electric organ acetylcholine receptors to muscle cells in culture caused loss of receptor by accelerating the rate of receptor degradation. Monovalent antibody fragments did not accelerate degradation unless antiantibody was added to cross-link the monovalent antibody fragments bound to receptors. This indicates that cross-linking of receptors by antibody molecules triggers accelerated receptor degradation, leading to receptor loss. The rate of increase in receptor destruction due to antigenic modulation observed in vitro appears sufficient to account for the extent of receptor loss observed in vivo. Endocytosis of antibody cross-linked receptors may be a rate-limiting step common to antigenic modulation in vitro and in vivo.
Similar articles
-
Antigenic modulation of human myotube acetylcholine receptor by myasthenic sera. Serum titer determines receptor internalization rate.J Immunol. 1986 May 1;136(9):3231-8. J Immunol. 1986. PMID: 3958494
-
Inhibition of alpha-bungarotoxin binding to acetylcholine receptors by antisera from animals with experimental autoimmune myasthenia gravis.J Supramol Struct. 1980;14(3):267-79. doi: 10.1002/jss.400140302. J Supramol Struct. 1980. PMID: 6971372
-
Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation.N Engl J Med. 1978 May 18;298(20):1116-22. doi: 10.1056/NEJM197805182982004. N Engl J Med. 1978. PMID: 643030
-
[Antibodies in myasthenia gravis].Rev Neurol (Paris). 2009 Feb;165(2):137-43. doi: 10.1016/j.neurol.2008.11.020. Epub 2009 Jan 21. Rev Neurol (Paris). 2009. PMID: 19162288 Review. French.
-
On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.Crit Rev Immunol. 2001;21(1-3):1-27. Crit Rev Immunol. 2001. PMID: 11642597 Review.
Cited by
-
Cholesterol modulates the rate and mechanism of acetylcholine receptor internalization.J Biol Chem. 2011 May 13;286(19):17122-32. doi: 10.1074/jbc.M110.211870. Epub 2011 Feb 28. J Biol Chem. 2011. PMID: 21357688 Free PMC article.
-
Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies.Proc Natl Acad Sci U S A. 1982 Jan;79(1):188-92. doi: 10.1073/pnas.79.1.188. Proc Natl Acad Sci U S A. 1982. PMID: 6948300 Free PMC article.
-
Effect of complement and its regulation on myasthenia gravis pathogenesis.Expert Rev Clin Immunol. 2008 Jan;4(1):43-52. doi: 10.1586/1744666X.4.1.43. Expert Rev Clin Immunol. 2008. PMID: 20477586 Free PMC article.
-
MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4.Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20783-8. doi: 10.1073/pnas.1313944110. Epub 2013 Dec 2. Proc Natl Acad Sci U S A. 2013. PMID: 24297891 Free PMC article. Clinical Trial.
-
Main immunogenic region structure promotes binding of conformation-dependent myasthenia gravis autoantibodies, nicotinic acetylcholine receptor conformation maturation, and agonist sensitivity.J Neurosci. 2009 Nov 4;29(44):13898-908. doi: 10.1523/JNEUROSCI.2833-09.2009. J Neurosci. 2009. PMID: 19890000 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources